Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 339.

https://doi.org/10.1182/blood-2024-194832

Published: 2024

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Blood (2023) 142 (17): 1438–1447.

https://doi.org/10.1182/blood.2022019173

Published: 2023

Includes: Supplemental data

Journal Articles

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Blood (2022) 140 (Supplement 1): 3638–3641.

https://doi.org/10.1182/blood-2022-165977

Published: 2022

Journal Articles

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Blood (2022) 140 (Supplement 1): 9688–9690.

https://doi.org/10.1182/blood-2022-157914

Published: 2022

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Michele Malagola, Nicola Polverelli, Massimo Martino, Vicky Rubini, Maria Teresa Lupo Stanghellini, Francesca Patriarca, Renato Fanin, Benedetto Bruno, Luisa Giaccone, Danilo Giuseppe Faraci, Giovanni Grillo, Stefania Bramanti, Luca Castagna, Paolo Bernasconi, Anna Amelia Colombo, Marco De Gobbi, Paolo Nicoli, Annalisa Natale, Stella Santarone, Elisabetta Terruzzi, Attilio Olivieri, Ilaria Scortechini, Patrizia Chiusolo, Elisabetta Metafuni, Angelo Michele Carella, Emanuela Merla, Marco Casini, Irene M Cavattoni, Mario Arpinati, Chiara Nozzoli, Ilaria Cutini, Patrizio Mazza, Annamaria Mazzone, Simona Bassi, Francesco Onida, Giorgia Saporiti, Filippo Antonio Canale, Adriana Vacca, Eugenia Piras, Piero Galieni, Sadia Falcioni, Mario Luppi, Giulia Debbia, Anna Paola Iori, Ursula La Rocca, Vincenzo Pavone, Anna Mele, Cristina Skert, Francesca Carobolante, Paola Carluccio, Carlo Borghero, Francesca Elice, Anna Proia, Fulvia Fanelli, Carmine Selleri, Nicoletta Sacchi, Sonia Mammoliti, Elena Oldani, Fabio Ciceri, Francesca Bonifazi, Domenico Russo

Blood (2021) 138 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2021-145970

Published: 2021

Journal Articles

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137075

Published: 2020

Journal Articles

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Blood (2019) 134 (Supplement_1): 4357.

https://doi.org/10.1182/blood-2019-122657

Published: 2019

Journal Articles

Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study

Paola Guglielmelli, MD PhD, Francesca Palandri, PhD MD, Carmine Selleri, MD, Daniela Cilloni, MD PhD, Francesco Mendicino, MD, Patrizio Mazza, MD, Domenico Pastore, MD PhD, Giuseppe A. Palumbo, MD, Sergio Siragusa, Prof, MD, Vincenzo Pavone, Stefana Impera, MD, Mara Morelli, MD, Francesco Passamonti, MD, Massimo Breccia, MD

Blood (2019) 134 (Supplement_1): 4179.

https://doi.org/10.1182/blood-2019-124730

Published: 2019

Journal Articles

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Blood (2018) 132 (Supplement 1): 920.

https://doi.org/10.1182/blood-2018-99-114442

Published: 2018

Journal Articles

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Carmen Martinez, MD PhD, Ariane Boumendil, PhD, Joanna Romejko-Jarosinska, Achilles Anagnostopoulos, Edgar Faber, MD, Xavier Poire, MD, Ibrahim Yakoub-Agha, MD PhD, Saad Akhtar, MD, Gunhan Gurman, Vincenzo Pavone, Kazimierz Halaburda, Aida Botelho Sousa, Herv Ghesquieres, Hervé Finel, Irma Khvedelidze, Silvia Montoto, MD, Anna Sureda, MD

Blood (2018) 132 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2018-99-112180

Published: 2018

Journal Articles

Ibrutinib, Single Agent BTK Inhibitor, for Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: A Real-Life Experience from Rete Ematologica Pugliese (REP)

Potito Rosario Scalzulli, MD, Attilio Guarini, MD, Giacomo Loseto, MD, Giorgina Specchia, Anna Maria Giordano, Domenico Pastore, MD PhD, Giovanni Quintana, MD, Patrizio Mazza, MD, Alessandro Maggi, Nicola Di Renzo, MD, Maria Rosaria De Paolis, Giuseppe Tarantini, Gaetano De Santis, MD, Vincenzo Pavone, Antonino Greco, MD, Maria Rosa Valvano, Statistician, Nicola Cascavilla, MD

Blood (2018) 132 (Supplement 1): 5557.

https://doi.org/10.1182/blood-2018-99-116441

Published: 2018

Journal Articles

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Blood (2016) 128 (22): 4161.

https://doi.org/10.1182/blood.V128.22.4161.4161

Published: 2016

NARROW

Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study

Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity

Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics

Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study

Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Ibrutinib, Single Agent BTK Inhibitor, for Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: A Real-Life Experience from Rete Ematologica Pugliese (REP)

Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only